Efficacy of recombinant activated factor VII (rFVIIa; NovoSeven®) in obstetrical haemorrhagic shock

被引：0
|
作者：
S Sobieszczyk
GH Breborowicz
B Kubiaczyk
T Opala
机构：
[1] University of Medical Sciences,Laboratory of Cardiovascular and Haemostasis Disorders, Department of Mother and Child Health
[2] University of Medical Sciences,Department of Perinatology and Gynaecology
[3] University of Medical Sciences,Department of Mother and Child Health
来源：
Critical Care | / 7卷 / Suppl 2期
关键词：
Emergency Medicine; Conventional Method; Prothrombin; Small Dose; Hemorrhagic Shock;
D O I：
10.1186/cc1994
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Efficacy of recombinant activated factor VII (NovoSeven) in two patients affected by acquired hemophilia with retroperitoneal hematoma
    Ciavarella, N
    Schiavoni, M
    Ettorre, C
    Gilibertri, MG
    Mascolo, E
    Stefanile, C
    Valenzano, E
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS346 - PS346
  • [22] Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven (R))
    Bartosh, Nicole S.
    Tomlin, Tara
    Cable, Christian
    Halka, Kathleen
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 53 - 58
  • [23] Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa)
    Tiede, A.
    Friedrich, U.
    Stenmo, C.
    Allen, G.
    Giangrande, P.
    Goudemand, J.
    Hay, C.
    Holmstrom, M.
    Klamroth, R.
    Lethagen, S.
    McKenzie, S.
    Miesbach, W.
    Negrier, C.
    Yuste, V. J.
    Berntorp, E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (06) : 1191 - 1199
  • [24] Angiographic documentation of the efficacy of recombinant activated factor VII (NovoSeven) to control diffuse bleeding in major trauma
    Van Der Schueren, B
    Hammer, F
    Verschuren, F
    Hantson, P
    Deneys, V
    Hermans, C
    THROMBOSIS AND HAEMOSTASIS, 2005, 94 (06) : 1327 - 1328
  • [25] A Comparison Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Congenital Factor VII Deficiency
    Faranoush, M.
    Abolghasemi, Hassan
    Toogeh, Gh.
    Karimi, M.
    Eshghi, P.
    Managhchi, M.
    Hoorfar, H.
    Dehdezi, B. Keikhaei
    Mehrvar, A.
    Khoeiny, B.
    Kamyar, K.
    Heshmat, R.
    Baghaeipour, M. R.
    Mirbehbahani, N. B.
    Fayazfar, R.
    Ahmadinejad, M.
    Naderi, M.
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2015, 21 (08) : 724 - 728
  • [26] Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
    Brackmann, HH
    Effenberger, W
    Hess, L
    Schwaab, R
    Oldenburg, J
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1998, 61 : 18 - 23
  • [27] Severe obstetric bleeding treated with recombinant activated factor VII (rFVIIa)
    Segal, S
    Shemesh, IY
    Blumental, R
    Yoffe, B
    Laufer, N
    Ezra, Y
    Levy, I
    Mazor, M
    Martinowitz, U
    2ND WORLD CONGRESS ON CONTROVERSIES IN OBSTETRICS, GYNECOLOGY & INFERTILITY, 2001, : 43 - 46
  • [28] Recombinant activated factor VII (rFVIIa) as salvage treatment for intractable hemorrhage
    Aggarwal A.
    Malkovska V.
    Catlett J.P.
    Alcorn K.
    Thrombosis Journal, 2 (1)
  • [29] Control of a persistent obstetric haemorrhage with activated recombinant factor VII (rFVIIA)
    Jakobsen, DJ
    Shemesh, IY
    Boksenbojm, PM
    Blumenntal, R
    Segal, S
    Yoffe, B
    Martinovitz, U
    INTENSIVE CARE MEDICINE, 2001, 27 : S173 - S173
  • [30] Recombinant activated factor VII (rFVIIa): Characterization, manufacturing, and clinical development
    Jurlander, B
    Thim, L
    Klausen, NK
    Persson, E
    Kjalke, M
    Rexen, P
    Jorgensen, TB
    Ostergaard, PB
    Erhardtsen, E
    Bjorn, SE
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (04): : 373 - 383
12345